La cadena de opciones muestra datos clave de las opciones de acciones de OmniAb a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para OmniAb..

OmniAb (NASDAQ:OABI) Bolsa, Cadena de Opciones

OMNIAB INC

OmniAb

OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.

Oil,Field,Site,,In,The,Evening,,Oil,Pumps,Are,Running

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ATER

OABI

ONVO

Las acciones en EE. UU. suben a mitad de jornada, lideradas por un crecimiento en energía. El Dow sube 200 pts y el petróleo repunta.

Wall Street en alza: Dow sube 200 puntos mientras el petróleo y el oro se mantienen firmes

OmniAb Inc

Morgan Stanley analyst Stephen Byrd maintains Spire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) with a Equal-Weight and raises the price target from $75 to $78.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Spire, Raises Price Target to $78

JP Morgan analyst John Ivankoe maintains Cheesecake Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) with a Underweight and lowers the price target from $55 to $48.

CAKE

JP Morgan Maintains Underweight on Cheesecake Factory, Lowers Price Target to $48

Morgan Stanley analyst Stephen Byrd maintains Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>) with a Equal-Weight and raises the price target from $88 to $91.

Morgan Stanley Maintains Equal-Weight on Southern, Raises Price Target to $91

Morgan Stanley analyst David Arcaro maintains Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>) with a Overweight and raises the price target from $85 to $86.

Morgan Stanley Maintains Overweight on Sempra, Raises Price Target to $86

Morgan Stanley analyst David Arcaro maintains Public Service Enterprise (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEG#NYSE">PEG</a>) with a Overweight and raises the price target from $96 to $100.

Morgan Stanley Maintains Overweight on Public Service Enterprise, Raises Price Target to $100

JP Morgan analyst John Ivankoe maintains Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) with a Neutral and lowers the price target from $185 to $184.

TXRH

JP Morgan Maintains Neutral on Texas Roadhouse, Lowers Price Target to $184

On Thursday, PTC Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) shared new data from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American College of Medical Genetics and Genomics (ACMG) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Annual Clinical Genetics Meeting</a>.
These data provide further evidence of the potential benefits of sepiapterin treatment for the full spectrum of phenylketonuria (PKU) patients.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42272846/ptc-therapeutics-inks-licensing-pact-with-novartis-worth-3-billion-for-huntingtons-program" rel="noreferrer noopener">PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington&#8217;s Program</a>
Phenylketonuria is an inherited disorder that increases the levels of a substance called <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44414358/ptc-therapeutics-presents-new-sepiapterin-data-from-ongoing-studies" rel="noreferrer noopener">phenylalanine in the blood</a>.
Untreated phenylketonuria can lead to brain damage, intellectual disabilities, behavioral symptoms or seizures.
&#8220;These new data provide further evidence of the meaningful benefit sepiapterin can provide for children and adults with PKU, including those with the most severe form of the disease,&#8221; said Matthew Klein, CEO of PTC Therapeutics. &#8220;Furthermore, the treatment benefit demonstrated in individuals with mutations not responsive to BH4 and consistent with classical disease phenotype support the potential to penetrate all key patient segments.&#8221;
Treatment includes a strict diet with limited protein.
Key data presented include:
<ul>
<li>Over 97% of subjects participating in the Phe tolerance protocol of the APHENITY open-label extension study demonstrate the ability to liberalize their diet while on sepiapterin treatment, with a mean increase in protein intake of 126%.</li>
<li>66% of subjects participating in the Phe tolerance sub study reached or exceeded the age-adjusted recommended daily allowance of protein intake for an individual without PKU, while maintaining control of blood Phe levels.</li>
<li>Genetic variant analysis of subjects participating in the APHENITY study demonstrates that over 70% had a Genotype-Phenotype Value (GPV) consistent with classical PKU.</li>
</ul>
PTC submitted FDA regulatory approval applications in 2024 for sepiapterin for children and adults with PKU, with a target regulatory <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n44024275/ptc-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2024-financial" rel="noreferrer noopener">action date of&nbsp;July 29, 2025</a>.
PTC also submitted several additional marketing authorization applications outside the U.S. for sepiapterin in 2024. The CHMP opinion on sepiapterin MAA is expected in the second quarter of 2025. A regulatory decision in Japan is expected in the fourth quarter of 2025.
Price Action: PTCT stock is down 0.18% at $56.88 on Thursday&#8217;s last check.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/buybacks/25/03/44415887/veon-reports-4-7-q4-sales-growth-as-digital-push-accelerates-eyes-double-digit-gains-in-2025" target="_blank" rel="noreferrer noopener">VEON Reports 4.7% Q4 Sales Growth As Digital Push Accelerates, Eyes Double-Digit Gains In 2025</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

General

PTCT

PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July

Morgan Stanley analyst David Arcaro maintains PPL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPL#NYSE">PPL</a>) with a Overweight and raises the price target from $35 to $38.

Morgan Stanley Maintains Overweight on PPL, Raises Price Target to $38

Popular meme coin Fartcoin (CRYPTO: FARTCOIN) is rebounding, leading to renewed optimism among traders for a <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43059996/fartcoin-jumps-15-trader-predicts-dogecoin-style-parabolic-run">sustained meme coin rally</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Fartcoin (CRYPTO: FARTCOIN)</td>
<td>&nbsp;$0.3912</td>
<td>$391.3 million</td>
<td>+13.4%&nbsp;</td>
<td>&nbsp;+43.3</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.1739</td>
<td>$25.8 billion</td>
<td>+0.9%&nbsp;</td>
<td>+3.1%&nbsp;</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001294</td>
<td>$7.6 billion</td>
<td>+1%&nbsp;</td>
<td>+6.7%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Unipcs <a href="https://x.com/theunipcs/status/1902456168754376885">indicated</a> he is up seven figures on his Fartcoin long. 
Despite being 85% down from all-time highs, he believes strong meme coins recover sharply. According to the trader, Fartcoin has still one of the &#8220;biggest mindshares,&#8221; with the rebund being an indicator thereof.
"If the bull run continues, a return to all-time highs is a matter of when, not if," he said.
Another trade sees Fartcoin in an accumulation phase, a critical period where big money is made. 
He argues that risk-reward is best now, not when the price reaches $2. "The only skill you need now is patience," he concluded.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">$FARTCOIN I don't have any idea about how long this accumulation is going to last but this is how bottoms are formed and where money is made. Now it's when R:R actually looks best, not at $2. Only skill you need now is patience. <a href="https://t.co/WFGdgd9TmI">pic.twitter.com/WFGdgd9TmI</a>
&mdash; Res (@resdegen) <a href="https://twitter.com/resdegen/status/1902620937096253798?ref_src=twsrc%5Etfw">March 20, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:&nbsp;
<ul>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/03/44399122/pepe-fartcoin-bonk-leapfrog-dogecoin-shiba-inu-in-momentum-as-traders-predict-bullish-momentum">Pepe, Fartcoin, Bonk Leapfrog Dogecoin, Shiba Inu In Momentum As Traders Predict Bullish Momentum</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$SHIB

Fartcoin Soars 13% In A Day Outpacing Dogecoin, Shiba Inu: Is A Return To All-Time Highs In The Cards?

Morgan Stanley analyst David Arcaro maintains Pinnacle West Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNW#NYSE">PNW</a>) with a Equal-Weight and raises the price target from $84 to $88.

Morgan Stanley Maintains Equal-Weight on Pinnacle West Capital, Raises Price Target to $88

Macro Economic Events

WIIM

Economics

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher on continued strength following Wednesday's Fed decision. Additionally, US Feb. existing home sales beat expectations.

JP Morgan analyst John Ivankoe maintains Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) with a Underweight and lowers the price target from $107 to $105.

SHAK

JP Morgan Maintains Underweight on Shake Shack, Lowers Price Target to $105

Morgan Stanley analyst Stephen Byrd maintains PG&amp;E (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) with a Underweight and raises the price target from $16.5 to $17.5.

Morgan Stanley Maintains Underweight on PG&E, Raises Price Target to $17.5

Morgan Stanley analyst Stephen Byrd maintains ONE Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGS#NYSE">OGS</a>) with a Equal-Weight and raises the price target from $68 to $70.

Morgan Stanley Maintains Equal-Weight on ONE Gas, Raises Price Target to $70

Morgan Stanley analyst David Arcaro maintains NextEra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>) with a Overweight and raises the price target from $95 to $97.

Morgan Stanley Maintains Overweight on NextEra Energy, Raises Price Target to $97

Morgan Stanley analyst Stephen Byrd maintains MGE Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGEE#NASDAQ">MGEE</a>) with a Underweight and raises the price target from $78 to $80.

MGEE

Morgan Stanley Maintains Underweight on MGE Energy, Raises Price Target to $80

JP Morgan analyst John Ivankoe maintains Restaurant Brands Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) with a Overweight and lowers the price target from $80 to $78.

JP Morgan Maintains Overweight on Restaurant Brands Intl, Lowers Price Target to $78

Morgan Stanley analyst David Arcaro maintains Idacorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDA#NYSE">IDA</a>) with a Equal-Weight and raises the price target from $126 to $131.

Comments

OmniAb

OmniAb (OABI) Opciones

OmniAb (NASDAQ:OABI) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL